{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"251"}]}],"title":"All AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"231"}]}],"title":"All Drug-related AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"91"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"3"}]}],"title":"Pleural effusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"74"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"28"}]}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"63"}]}],"title":"Muscle spasms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"50"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"49"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"46"}]}],"title":"Headache"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"51"}]}],"title":"Pyrexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"54"}]}],"title":"Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"70"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"22"}]}],"title":"Drug-related SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"26"}]}],"title":"AEs leading to discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"}]}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"258"}],"units":"Participants"}],"description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From date of last person, first visit to date of last person, last visit (approximately 8 years)","title":"Number of Participants With Adverse Events (AEs), Drug-related AEs, Drug-related Serious Adverse Events (SAEs), Drug-related AEs Leading to Discontinuation, and All Deaths","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}